Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
, 24 (10), 1197-1203

Systemic Chemotherapy for Gastric Cancer With Early Recurrence After Adjuvant S-1 Monotherapy: A Multicenter Retrospective Study

Affiliations
Multicenter Study

Systemic Chemotherapy for Gastric Cancer With Early Recurrence After Adjuvant S-1 Monotherapy: A Multicenter Retrospective Study

Seiichiro Mitani et al. Int J Clin Oncol.

Abstract

Background: S-1 monotherapy is one of the standard adjuvant treatments for patients with stage II and III gastric cancers. Early recurrence after S-1 adjuvant therapy has a poor prognosis. This study aimed to clarify the treatment outcomes of systemic chemotherapy and explore encouraging regimens.

Methods: This was a multicenter retrospective study. Among gastric cancer patients who underwent curative gastrectomy followed by adjuvant S-1 monotherapy, patients who experienced a recurrence while receiving adjuvant therapy or within 6 months after completion and started systemic chemotherapy at four institutions between 2005 and 2015 were eligible.

Results: A total of 112 patients were included. The main treatment regimens were weekly paclitaxel (n = 38, 34%), irinotecan plus cisplatin (n = 31, 28%), capecitabine plus cisplatin (n = 7, 6%), and irinotecan monotherapy (n = 6, 5%). For all patients, median progression-free survival and overall survival were 3.7 and 11.4 months, respectively. Among 77 patients with measurable lesions, the overall response and disease control rates were 24.7% and 62.3%, respectively. Multivariate analyses for overall survival showed that Eastern Cooperative Oncology Group performance status 2 [hazard ratio (HR) 3.71; 95% confidence interval (CI) 1.78-7.73] and undifferentiated histological type (HR 2.04; 95% CI 1.35-3.44) were independent prognostic factors, and treatment regimens were not prognostic. Exploratory comparisons did not show statistically significant differences between treatment regimens.

Conclusions: This study of the largest number of patients with early recurrence after S-1 adjuvant monotherapy demonstrated that the prognosis for patients treated by all regimens was similar and poor.

Keywords: Adjuvant chemotherapy; Gastric cancer; Recurrence.

Similar articles

See all similar articles

References

    1. J Clin Oncol. 2004 Jun 15;22(12):2395-403 - PubMed
    1. N Engl J Med. 2007 Nov 1;357(18):1810-20 - PubMed
    1. Lancet Oncol. 2008 Mar;9(3):215-21 - PubMed
    1. Jpn J Clin Oncol. 2008 Nov;38(11):786-9 - PubMed
    1. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback